



**ASX & Media Release**

## **Section 708A Cleansing Statement**

18 June 2025

This notice is given by Patrys Limited ACN 123 055 363 (**ASX: PAB**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) it has today issued a total of 308,362,535 fully paid ordinary shares (**Shares**) at an issue price of \$0.001 per Share, in relation to the Placement to sophisticated and professional investors, pursuant to Section 708 of the *Corporations Act 2001* (Cth), as announced on 10 June 2025.
- (b) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) The Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

An Appendix 2A relating to the issue of Shares was lodged earlier today.

**-Ends-**

**For and on behalf of the Board of Directors and for further information, please contact:**

**General enquiries**

James Campbell  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

**Media enquiries:**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Registered Office Address**

Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000

**About Patrys Limited**

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at [www.patrys.com](http://www.patrys.com).